Eisai, Biogen say FDA grants priority review for Alzheimer’s drug lecanemab

, ,
Leqembi

Eisai, Biogen say FDA grants priority review for Alzheimer’s drug lecanemab

TOKYO, March 6 (Reuters) – Japanese drugmaker Eisai Co. Ltd. (4523.T) and its U.S. partner Biogen Inc. (BIIB.O) said on Monday that the U.S. Food and Drug Administration granted priority review for traditional approval of their Alzheimer’s treatment lecanemab.

The FDA accepted Eisai’s supplemental Biologics License Application for the drug, supporting transition from the accelerated approval granted in January, the drugmaker said in a statement.

Reporting by Rocky Swift; editing by Diane Craft

Our Standards: The Thomson Reuters Trust Principles.

 

/by
You might also like
BiogenBiogen to discontinue development of older Alzheimer’s drug Aduhelm
Novavax COVID shot, aimed at vaccine skeptics, overwhelmingly backed by FDA panel
Ivan Cheung, EisaiDespite regulatory progress, delivery hurdles persist for neurodegenerative space
Juul e-cigarettes to be ordered off U.S. shelves – WSJ
FDAReutersU.S. FDA approves first treatment for severe frostbite
LeqembiEisai-Biogen Alzheimer’s drug data confirms benefits, FDA staff says
EisaiJapan’s Eisai says US introduction of Alzheimer’s drug Leqembi slower than expected
FDA pushes back review period for Provention Bio’s diabetes drug